Literature DB >> 625497

Evaluation of prognosis in Stage I cutaneous melanoma.

A Breslow, S D Macht.   

Abstract

A review of the literature on melanoma indicates that age, sex, size, ulceration, presence of satellites, absence of melanin, and whether or not the tumor is markedly raised above the surface of the surrounding skin are all useful criteria in evaluating the prognosis in Stage I cutaneous melanoma. Histological factors include the tumor type, the mitotic rate, and the maximum thickness of the tumor. The last is accurate for prognosis--objective, reproducible, and directly proportional to the mortality rate. Tumors less than 0.76 mm thick rarely, if ever, metastasize--and it appears that the size of the resection margin can safely be reduced for such thin tumors. The level of invasion (Clark) is less accurate in predicting the mortality.

Entities:  

Mesh:

Year:  1978        PMID: 625497     DOI: 10.1097/00006534-197803000-00006

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  11 in total

1.  Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up.

Authors:  Torsten Hinz; Hojjat Ahmadzadehfar; Anja Wierzbicki; Tobias Höller; Jörg Wenzel; Hans-Jürgen Biersack; Thomas Bieber; Monika-H Schmid-Wendtner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

2.  Reasons for poor prognosis in British patients with cutaneous malignant melanoma.

Authors:  V R Doherty; R M MacKie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

Review 3.  Role of primary care in the prevention of malignant melanoma.

Authors:  N Johnson; D Mant; J Newton; P L Yudkin
Journal:  Br J Gen Pract       Date:  1994-11       Impact factor: 5.386

4.  Tumor thickness as a prognostic guide to melanoma.

Authors:  S D Macht
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

5.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

6.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  Prognostic value of tumour thickness in cutaneous malignant melanoma.

Authors:  I Jeffrey; P Royston; C Sowter; G Slavin; A Price; A Pomerance; S Goolamali; D Pinto
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

8.  Adjuvant BCG immunotherapy for stage I and II malignant melanoma.

Authors:  H K Silver; E M Ibrahim; J A Evers; J W Thomas; R N Murray; J J Spinelli
Journal:  Can Med Assoc J       Date:  1983-06-01       Impact factor: 8.262

9.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

10.  Cutaneous malignant melanoma in Scotland.

Authors:  R M MacKie; J A Hunter
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.